Is a Hematocrit of 51% Too High on TRT? (TRT Q&As)
Timeline
The member says his hematocrit historically stayed around 45–48% but increased after starting testosterone injections. Dr. O’Connor explains that the number should not be interpreted in isolation and considers clotting history, cardiovascular disease, blood pressure, genetics, iron studies, and other risk factors before deciding whether intervention is needed.
Dr. O’Connor asks about blood pressure as part of assessing the member’s overall cardiovascular and thrombotic risk rather than judging hematocrit alone. The member reports well-controlled blood pressure, which Dr. O’Connor considers reassuring in the broader clinical picture.
Dr. O’Connor explains that another patient has rising ferritin and abnormal iron studies suggesting a tendency toward iron deposition, making his situation different despite similar CBC values. He emphasizes that managing men on androgens requires combining hemoglobin and hematocrit with iron studies, genetics, medical history, and other risk factors.
The member asks whether a single blood donation would be worthwhile despite having no symptoms or other major risk factors. Dr. O’Connor says routine phlebotomy is not supported simply because of this hematocrit level and warns that unnecessary repeated blood removal can deplete iron and eventually cause fatigue.
The member reports a small change in his cholesterol results. Dr. O’Connor reviews the HDL and LDL in context, explains that HDL is no longer treated as an independent risk variable, and considers the small LDL change within normal biological variation rather than a major deterioration.
Dr. O’Connor says the hematocrit should continue to be monitored but does not see a need for aggressive intervention based on the current overall picture. If the member remains uncomfortable with the number, occasional blood donation could be considered, but he strongly cautions against frequent phlebotomy that can unnecessarily deplete iron.
Video Summary
A weekly live Q and A format is described, and an excerpt focuses on hormone monitoring details. A participant explains a twice weekly injection schedule spaced about three and a half days apart. The timing is specified as Tuesday evening and Saturday morning to split the week evenly. To understand peaks and troughs, four morning blood tests are taken between the injections. One draw uses a full ABCDS™ panel ordered through a clinician, and others are narrower repeats. The aim is to map total and free testosterone values from twelve hours after dosing to trough. The report suggests total testosterone stayed unexpectedly flat across the interval with one dip day. A possible explanation offered is measurement variability rather than a true physiologic swing.
The conversation compares prior gel use with injections and notes that free values were once lower. Dose history is mentioned, including a prior weekly amount around one hundred twenty five milligrams. A current weekly dose around one hundred fifteen milligrams is described during the tracking campaign. The discussion then pivots to hematocrit and hemoglobin, described as drifting upward historically. A screening style approach is used, asking about embolism, hypertension, cardiac disease, and strokes. Polycythemia vera is mentioned as a distinct disease category, while stating the case does not match it. The segment cautions against managing therapy by chasing single cutoffs without broader patient context. It stresses that symptoms and trends matter more than isolated numbers copied from lab reference ranges.
Iron studies are brought into the discussion, and ABCDS™ are referenced with D tied to iron deposition. Ferritin is discussed as a marker that can rise, and phlebotomy is mentioned in severe deposition cases. Sleep apnea and diet are discussed as contributors that can influence hemoglobin and hematocrit readings. The segment explains that hemoglobin molecules carry oxygen and contain elemental iron at their core. It argues that red blood cell values cannot be interpreted without considering iron availability and drivers. Later remarks note that some variation is statistical and does not automatically signal a dangerous problem. A practical takeaway is to use consistent timing, repeated measurements, and full context for decisions. The closing frames tracking as a tool to reduce guesswork when adjusting hormones and monitoring safety.
Drug Callouts
Condition Callouts
Key Takeaways
- Twice weekly injections were tracked with morning labs to map hormone stability.
- Reported total testosterone stayed unusually flat with one dip likely from variability.
- Hematocrit interpretation was framed around symptoms, trends, and embolism screening questions.
- ABCDS™ and iron deposition concepts were used to explain ferritin and iron study relevance.
- Sleep apnea, diet, and statistical variation were discussed as modifiers of blood count readings.